跌够了！港股通创新药ETF（520880）放量反弹，阶段拐点到了？政策放大招，2.38亿资金已进场

Market Performance - After a six-day decline, the Hong Kong Stock Connect Innovation Drug ETF (520880) rebounded on January 23, rising over 2% at one point and closing up 1.53% with a trading volume of 348 million yuan [1][7] - Key constituent stocks such as Cloudtop New Drug led the gain with an 8.2% increase, while major stocks like Kangfang Biotech and CSPC Pharmaceutical rose by 3.5% [1][7] Policy Developments - On January 22, the Ministry of Commerce and nine other departments issued a document promoting high-quality development in the pharmaceutical retail industry, encouraging innovative drugs and reference preparations to enter retail pharmacy sales channels [3][9] - This policy is expected to provide a pathway for high-value innovative drugs, such as CAR-T, to fill the insurance coverage gap through commercial insurance directories [3][9] - The insurance industry association estimates that by 2025, the total compensation amount for innovative drugs and devices from commercial health insurance will reach approximately 14.7 billion yuan, with a compound annual growth rate of 70% over four consecutive years [3][9] Industry Insights - At the recent JPM conference, Chinese pharmaceutical companies showcased technological breakthroughs in areas such as ADC, IO dual antibodies, and GLP-1, moving towards global markets through licensing and collaborative development [3][9] - According to CITIC Securities, the Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 being a critical year for validating transformation effectiveness [3][9] Investment Opportunities - The Hong Kong Stock Connect Innovation Drug ETF (520880) is highlighted as a high-elasticity T+0 investment tool, with its index (Hang Seng Hong Kong Stock Connect Innovation Drug Select Index) offering three unique advantages: 1. Purely innovative drugs with 100% purity, covering companies focused on innovative drug R&D [5][11] 2. A significant concentration of leading companies, with the top ten innovative drug leaders accounting for over 73% of the index [5][11] 3. Enhanced risk control through forced de-weighting of less liquid constituent stocks [5][11] Constituent Stocks - The top ten constituent stocks of the Hong Kong Stock Connect Innovation Drug ETF (520880) have a combined weight of 73.41%, showcasing a strong representation of leading companies in the innovative drug sector [6][12] - Notable constituents include: - Kangfang Biotech: 10.49% weight, market cap of 110.9 billion HKD - BeiGene: 10.01% weight, market cap of 312 billion HKD - CSPC Pharmaceutical: 9.97% weight, market cap of 102.1 billion HKD [6][12]